A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine

Trial Profile

A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 24 Oct 2017 According to Biohaven Pharmaceutical Holding Company media release, data from this trial are expected to support a potential NDA submission in the first half of 2019.
    • 11 Sep 2017 Status changed from not yet recruiting to recruiting, according to a Biohaven Pharmaceutical Holding Company media release.
    • 01 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top